These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28798303)

  • 1. Understanding the molecular basis of agonist/antagonist mechanism of human mu opioid receptor through gaussian accelerated molecular dynamics method.
    Wang YT; Chan YH
    Sci Rep; 2017 Aug; 7(1):7828. PubMed ID: 28798303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.
    Cheng JX; Cheng T; Li WH; Liu GX; Zhu WL; Tang Y
    Acta Pharmacol Sin; 2018 Jan; 39(1):154-164. PubMed ID: 29188799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand based conformational space studies of the μ-opioid receptor.
    Sena DM; Cong X; Giorgetti A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129838. PubMed ID: 33373630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico studies of conformational dynamics of Mu opioid receptor performed using gaussian accelerated molecular dynamics.
    Liao JM; Wang YT
    J Biomol Struct Dyn; 2019 Jan; 37(1):166-177. PubMed ID: 29277141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into µ-opioid receptor activation.
    Huang W; Manglik A; Venkatakrishnan AJ; Laeremans T; Feinberg EN; Sanborn AL; Kato HE; Livingston KE; Thorsen TS; Kling RC; Granier S; Gmeiner P; Husbands SM; Traynor JR; Weis WI; Steyaert J; Dror RO; Kobilka BK
    Nature; 2015 Aug; 524(7565):315-21. PubMed ID: 26245379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.
    Wang H; Cao D; Gillespie JC; Mendez RE; Selley DE; Liu-Chen LY; Zhang Y
    Future Med Chem; 2021 Mar; 13(6):551-573. PubMed ID: 33590767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To probe interaction of morphine and IBNtxA with 7TM and 6TM variants of the human μ-opioid receptor using all-atom molecular dynamics simulations with an explicit membrane.
    Sader S; Anant K; Wu C
    Phys Chem Chem Phys; 2018 Jan; 20(3):1724-1741. PubMed ID: 29265141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for the mu opioid receptor in the antidepressant effects of buprenorphine.
    Robinson SA; Erickson RL; Browne CA; Lucki I
    Behav Brain Res; 2017 Feb; 319():96-103. PubMed ID: 27818236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).
    DiMattio KM; Chen C; Shi L; Liu-Chen LY
    Eur J Pharmacol; 2015 Feb; 748():93-100. PubMed ID: 25481857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators.
    Wang H; Reinecke BA; Zhang Y
    J Comput Aided Mol Des; 2020 Aug; 34(8):879-895. PubMed ID: 32193867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propagation of conformational changes during μ-opioid receptor activation.
    Sounier R; Mas C; Steyaert J; Laeremans T; Manglik A; Huang W; Kobilka BK; Déméné H; Granier S
    Nature; 2015 Aug; 524(7565):375-8. PubMed ID: 26245377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. μ Opioid receptor: novel antagonists and structural modeling.
    Kaserer T; Lantero A; Schmidhammer H; Spetea M; Schuster D
    Sci Rep; 2016 Feb; 6():21548. PubMed ID: 26888328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic prevention of mu-opioid receptor (MOR) G-protein coupling in the pontine parabrachial nucleus persistently decreases consumption of standard but not palatable food.
    Ward HG; Simansky KJ
    Psychopharmacology (Berl); 2006 Sep; 187(4):435-46. PubMed ID: 16847679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic and thermodynamic insights into sodium ion translocation through the μ-opioid receptor from molecular dynamics and machine learning analysis.
    Hu X; Wang Y; Hunkele A; Provasi D; Pasternak GW; Filizola M
    PLoS Comput Biol; 2019 Jan; 15(1):e1006689. PubMed ID: 30677023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
    Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
    Wang D; Sun X; Sadee W
    J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral μ-opioid receptor mediated inhibition of calcium signaling and action potential-evoked calcium fluorescent transients in primary afferent CGRP nociceptive terminals.
    Baillie LD; Schmidhammer H; Mulligan SJ
    Neuropharmacology; 2015 Jun; 93():267-73. PubMed ID: 25721395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Docking, Molecular Dynamics, and Structure-Activity Relationship Explorations of 14-Oxygenated N-Methylmorphinan-6-ones as Potent μ-Opioid Receptor Agonists.
    Noha SM; Schmidhammer H; Spetea M
    ACS Chem Neurosci; 2017 Jun; 8(6):1327-1337. PubMed ID: 28125215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.